Merck's Zolina shows antitumor activity; PolyMedix gets $14M;

 @FierceBiotech: Explosion of cancer drug trials spurs a new approach. Article | Follow @FierceBiotech

 @JohnCFierce: Tengion is looking for $35M out of an IPO this week. The strategy: Aim real low and keep your fingers crossed. Article | Follow @JohnCFierce

> According to research published in The Lancet, Merck's cancer drug Zolina shows promising antitumor activity and is well tolerated when combined with short-term palliative radiotherapy in patients with advanced pelvic cancer. Article

> Ambrilia Biopharma and its subsidiary Cellpep Pharma have approved a proposed transaction in which Ambrilia and Cellpep would receive additional non-dilutive financing through the disposition of a limited partnership interest. Before expenses to be incurred in connection with this potential transaction, a gain in the amount of approximately $4M could be realized by Ambrilia and Cellpep upon the closing. Ambrilia release

> Hercules Technology Growth Capital will provide PolyMedix $14 million in credit facilities. PolyMedix anticipates that proceeds from the facility may be used to fund certain Phase III enabling activities for its two lead compounds, PMX-60056 and PMX-30063, including manufacturing and toxicology studies, as well as for other general corporate purposes. Release

> Roche's Genentech is just weeks away from starting to ramp up production at its $400 million campus in Hillsboro, Oregon. Report

And Finally... An analysis of dietary data from more than 400,000 men and women found only a weak association between high fruit and vegetable intake and reduced overall cancer risk. Report

Suggested Articles

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.

Lilly has created customized mobile research units to run the clinical trial as the long-term care facilities lack experience running studies.

After its mega $424 million IPO this summer, blood cancer focused Legend Biotech is making a big change at the top.